The purpose of this study is to assess the efficacy and safety of bupropion in reducing methamphetamine use in subjects with methamphetamine dependence

Condition	Treatment or Intervention	Phase
Amphetamine-Related Disorders	Drug: Bupropion	Phase II

Further Study Details: 

Expected Total Enrollment:  150

A double-blind, placebo-controlled, parallel-group design study in which 100 subjects will be randomly assigned to placebo or bupropion for 12 weeks with follow-up assessments 4 weeks following treatment. Adaptive randomization will be used to balance treatment groups based on gender.

Ages Eligible for Study:  18 Years   -   65 Years,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria:

• Subject must have methamphetamine dependence as determined by the DSM-IV diagnosis
• Subject must be willing to comply with study procedures.
• Ability to verbalize understanding of consent form, provide written consent, and verbalize willingness to complete study procedures
• Be able to comply with protocol requirements

Exclusion Criteria:

• Please contact site for more information.

California
      South Bay Treatment Center, San Diego,  California,  92105,  United States
      Matrix Institute on Addictions, Costa Mesa,  California,  92627,  United States
Hawaii
      Pacific Addiction Research Center, Honolulu,  Hawaii,  96813,  United States
Iowa
      Powell Chemical Dependency Center, Des Moines,  Iowa,  50316,  United States
Missouri
      University of Missouri - Kansas City, Kansas City,  Missouri,  64108,  United States

Study chairs or principal investigators

Richard Rawson, Ph.D.,  Principal Investigator,  University of California, Los Angeles   

Study ID Numbers:  NIDA-CTO-0008-1
Record last reviewed:  March 2005
Last Updated:  March 24, 2005
Record first received:  September 18, 2003
ClinicalTrials.gov Identifier:  NCT00069251
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08